R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023

... 0.12%, is a therapeutic drug for glaucoma and ocular hypertension and has been marketed in Japan since ... systemic adverse reactions demonstrates steady ocular pressure-decreasing action by twice-a-day ... realized through its optic nerve protection and ocular blood flow-increasing mechanism. Concerning ...

ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease

... in subjective symptoms measured by the ocular Surface Disease Index (OSDI) and improvement in patients' most bothersome ocular symptoms. "The strong clinical results from ... symptoms (OSDI and patient's most bothersome ocular symptoms), when administered under normal ...

ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting

... Bepreve 1.5% was effective at reducing ocular itching for at least 8 hours after dosing, with high statistical significance for improvement in ocular itching compared to placebo for up to 16 hours ... Besilate Ophthalmic Solution 1.5% Reduces ocular Itching Following Dosing in the Conjunctival ...

Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting

... results from a separate six month intravitreal ocular biodistribution study, shows the presence of ... have shown activity in both animal models of ocular disease and in human clinical trials. The ... drug development company focusing on cancer, ocular diseases (macular degeneration, diabetic ...

Lions Eye Institute for Transplant & Research, Inc. Launches Multi-Million Dollar, State-of-the-Art Research Institute that Will Advance the Study of Blinding Eye Diseases

... will offer high-volume, high-quality human ocular tissue for research, study, collaboration, and ... with blinding diseases." Transforming ocular Research Key to the successful advancement of ocular tissue research is having the highest quality ...

ARVO, AOS: Large Study of Lacrisert(R) Dry Eye Insert;

... Patients Experience Significant Improvement in ocular Surface Disease and Quality of Life ... PM). As reported by Dr. Koffler, mean ocular surface disease index (OSDI) total scores for ... weeks is especially noteworthy, suggesting that ocular health and quality of life for dry eye sufferers ...

Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis

... and symptoms (itching and redness) of persistent ocular allergic inflammation. A one-week pre-treatment ... of Ora, Inc. "Patients with a history of chronic ocular background inflammation make up a large segment of the ocular allergy market, and are also patients that tend ...

Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

... inflammation and pain associated with ocular surgery. A supplemental New Drug Application ... of N -(4-hydroxyphenyl) Retinamide in ocular Tissue Session Date/Start Time: Sunday May ... portfolio which includes products that address ocular diseases and conditions including uveitis, ...

Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma

... the 9th Scientific Meeting of the Association for ocular Pharmacology and Therapeutics (AOPT) held in ... France. Acute toxicological studies confirmed the ocular surface toxicity of anti-glaucomatous eye ... stress conditions. Nova21027 is a topical ocular BAK-free emulsion of latanoprost relying ...

ESBATech's Antibody Fragment Enters Phase Ib/IIa in Ophthalmology

... to evaluate the safety, tolerability, and ocular pharmacokinetics (PK) of topically applied ... as well as assess the preventive activity on ocular inflammation resulting from the surgery. ESBA105 ... development of novel treatments for inflammatory ocular conditions. We are very pleased to advance our ...

ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium

... group in subjective symptoms as measured by the ocular Surface Disease Index (OSDI) or patient's worst ... and placebo groups, and there were no serious ocular or systemic adverse events. Another ... industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The ...

ISTA Pharmaceuticals' New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration

... approval for Bepreve as an eye drop treatment for ocular itching associated with allergic conjunctivitis. ... reductions in the primary endpoints of ocular itching. In addition, the results showed ... response and on additional signs or symptoms of ocular allergy, including improvement in nasal symptoms. ...

ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%

... the primary efficacy endpoint of absence of ocular inflammation 15 days following surgery. In ... the secondary efficacy endpoint of elimination of ocular pain one day post surgery. When ... ER exhibited strong trends in both the absence of ocular inflammation and pain but did not meet ...

Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented

... of inflammation and pain associated with ocular surgery. (Logo: ... of the leading causes of blindness, uveitis and ocular herpes," said Barry Butler, President and CEO of ... gel, available in Europe for the treatment of ocular viral infections for more than 10 years. Herpes ...

Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)

... of inflammation and pain associated with ocular surgery; it was approved by the US Food and ... not contain benzalkonium chloride (BAK), a common ocular preservative known to cause corneal toxicity ... trend continued through Day 42. ocular discomfort and pain is a debilitating symptom of ...

Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain

... in 245 patients undergoing unilateral ocular surgery. In the first study of 124 patients, ... than placebo in treating postoperative ocular inflammation and relieving ocular pain/discomfort as early as Day 3/4." A ...

ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing

... Company Will Seek Label for the Treatment of ocular Itching Associated with ... concentrations in 130 patients with a history of ocular allergies. Both concentrations demonstrated ... in total nasal symptoms. There were no serious ocular adverse events reported in patients dosed with ...

ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation

... secondary efficacy endpoints of elimination of ocular pain and mean reduction of markers of ... of bromfenac produced a low overall incidence of ocular adverse events. "We undertook this trial in ... anti-inflammatory compound for the treatment of ocular inflammation and pain. Xibrom, approved in 2005, ...

OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection

... Against Acanthamoeba Keratitis, a Serious ocular Infection- -Provides Additional Evidence That ... vision impairment or blindness. AK, which in its ocular form most commonly infects contact lens wearers, ... rights to a proprietary formulation of NCT for ocular uses from Pathogenics, Inc. OPKO is currently ...

ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting

... both the primary efficacy endpoint of absence of ocular inflammation 15 days following surgery and the secondary efficacy endpoint of elimination of ocular pain at day one. In addition, compared to placebo, bromfenac produced a lower overall incidence of ocular adverse events. William B. Trattler, ...

Sirion Therapeutics Announces Positive Phase III Results for Difluprednate

... rapidly resolve inflammation in the eye following ocular surgery. "We are very pleased with the data that ... investigator in the trial. "Being able to treat ocular inflammatory disease with a more convenient ... to offer rapid resolution of inflammation after ocular surgery would represent a meaningful advance for ...

Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501

... Phase 2 Drug Candidate Protects the ocular Surface Following Exposure to Controlled ... the total cornea-a measure of damage to the ocular surface-than those who received vehicle (p < ... the disruption of the epithelial barrier on the ocular surface. Alacrity acquired the worldwide rights ...

Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual

... of its pivotal Phase III clinical trial treating metastatic cutaneous and ocular melanoma to the liver. The participating cancer centers in this trial ... of melphalan to the liver to treat patients with metastatic cutaneous and ocular melanoma who have unresectable tumors in the liver. The Delcath System is ...

Potentia Pharmaceuticals' POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II

... The current POT-4 formulation is expected to provide sustained therapeutic ocular levels of the drug for several months following a single injection. ... the approximately 10-15% of AMD patients with complications resulting from ocular angiogenesis (growth of new blood vessels and bleeding in the back of the ...

Dr. James F. Pingpank to Present at Leading Regional Therapies Conference

... Adjunct Principal Investigator of Delcath's Phase III Trial treating ocular and cutaneous melanoma metastatic to the liver, and Principal Investigator ... of melphalan to the liver to treat patients with metastatic cutaneous and ocular melanoma who have unresectable tumors in the liver. The Delcath PHP ...

GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP

... study, cataracts developed or worsened in 4% of patients who underwent ocular examination prior to therapy with PROMACTA. Cataracts were observed in toxicology studies of eltrombopag in rodents. Perform a baseline ocular examination prior to administration of PROMACTA and, during therapy with ...

FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder

... study, cataracts developed or worsened in 4% of patients who underwent ocular examination prior to therapy with PROMACTA. Cataracts were observed in toxicology studies of eltrombopag in rodents. Perform a baseline ocular examination prior to administration of PROMACTA and, during therapy with ...

Encouraging Gene Therapy Results in Genetic Form of Blindness

... "Phase I Trial of Leber Congenital Amaurosis due to RPE65 Mutations by ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term ... adverse events, immune reactions, or systemic toxicity. "Human ocular gene therapy for inherited retinal disease is undergoing a birth ...

Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration

... an important milestone for this compound intended to treat a devastating ocular disease that impacts millions of people worldwide." "New therapies are ... VEGF Trap-Eye for treatment of wet AMD, diabetic eye diseases, and other ocular diseases and disorders. Once approved, Bayer HealthCare will market VEGF ...

Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema

... the back of the eye expected to combine ease of use, sustained release and ocular safety. Administering this emulsion through a single injection can offer ... has developed a broad pipeline of 7 innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include ...

Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs

... oxide-donating prostaglandin F2-alpha analog, at the Association for ocular Pharmacology and Therapeutics 8th Scientific Meeting. NicOx and Pfizer ... This collaboration involves several separate projects focused on major ocular diseases and encouraging results have been observed in the most advanced ...

MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration

... 2 trials in both of these important indications, as well as additional ocular diseases and conditions." MacuSight intends to complete its collection ... serve as a potentially highly-efficacious therapeutic for a wide range of ocular diseases and conditions, including the treatment and prevention of wet ....

New Data Shows Veramyst Effectively Treats Symptoms of Perennial Allergic Rhinitis

... Spray demonstrated significant improvement in the treatment of nasal and ocular allergy symptoms of perennial allergic rhinitis (PAR) in patients 12 years ... the efficacy of Veramyst for patients suffering from both nasal and ocular symptoms all year long, not just during spring and fall allergy seasons," ...

Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process

... plans to file a second IND early next year for the use of iSONEP(TM) (the ocular formulation of humanized Sphingomab) for the treatment of AMD. The company ... of cancer and other diseases. A second product candidate, iSONEP(TM) (the ocular formulation of humanized Sphingomab), has demonstrated superior results in ...

Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates

... profile of Sphingomab bolsters not only our cancer program, but also our ocular program, because the drug substance is humanized Sphingomab in both ... of cancer and other diseases. A second product candidate, iSONEP(TM) (the ocular formulation of humanized Sphingomab), has demonstrated superior results in ...

Novagali Pharma Completed a New Phase II With Cyclokat(R) in Dry Eye

... products. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), for treatment of vernal keratoconjunctivitis, Cyclokat(R), for the ...

Cancer Research 'David' Hopes to Slay 'Cancer Goliath'

... pancreas, prostate, ovary, and stomach. In addition, some effectiveness was seen in an instance of lymphoid leukemia, and one of a glioma of the ocular nerve. These tests preceded his more recent death due to an unfortunate accident. As a small Foundation hard hit by the untimely death of their ...

Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program

... Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular ...

ExonHit Therapeutics Expands Strategic Collaboration With Allergan

... of a single payment. The scope of the collaboration is expanded to include epitope* discovery for the development of antibody therapeutics in ocular disorders. ExonHit's unique gene profiling technology can readily be applied to identify disease specific target proteins, but also pinpoints novel ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... considered in combination with a short period of oral steroid administration. Auditory (high-frequency hearing loss, decreased hearing) and ocular (lens opacities, cataracts, elevations in intraocular pressure and retinal disorders) disturbances have been reported with Exjade therapy in less ...